Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: Roles of Nrf2 and NF-κB

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 4, 2013, Pages

  Wang, Yuehui ^a   Sun, Weixia ^a,b   Du, Bing ^a   Miao, Xiao ^a,b   Bai, Yang ^a,b   Xin, Ying ^b,c   Tan, Yi ^b,d   Cui, Wenpeng ^a,b   Liu, Bin ^a   Cui, Taixing ^d,e   Epstein, Paul N ^b,f   Fu, Yaowen ^a   Cai, Lu ^b,d,f  

^a JILIN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

^c Basic Medical College   (China)

^d WENZHOU MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Diabetic cardiomyopathy; MG132; Nuclear factor erythroid 2 related factor 2; Nuclear factor B; Proteasome inhibitor; Therapeutic effect

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; ANTIOXIDANT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEASOME; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION; HEART DISEASE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE SIZE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOPATHOLOGY; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DNA BINDING; TIBIA; UPREGULATION;

ANIMALS; ANTIOXIDANTS; CYSTEINE PROTEINASE INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HYPERTROPHY, LEFT VENTRICULAR; LEUPEPTINS; MICE; MICE, TRANSGENIC; MYOCARDITIS; NF-E2-RELATED FACTOR 2; NF-KAPPA B; OXIDATIVE STRESS; PROTEASOME INHIBITORS;

EID: 84874051303     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00650.2012     Document Type: Article

References (39)

1. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 1: 181-193, 2001.
2. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, Kang YJ. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 48: 1688-1697, 2006.
3. Campbell B, Adams J, Shin YK, Lefer AM. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 31: 467-476, 1999.
4. Chen B, Ma Y, Meng R, Xiong Z, Zhang C, Chen G, Zhang A, Dong Y. MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals. Acta Biochim Biophys Sin (Shanghai) 42: 253-258, 2010.
5. Chen J, Regan RF. Increasing expression of heme oxygenase-1 by proteasome inhibition protects astrocytes from heme-mediated oxidative injury. Curr Neurovasc Res 2: 189-196, 2005.
6. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65: 801-847, 1996.
7. Cui W, Bai Y, Li B, Miao X, Chen Q, Sun W, Tan Y, Luo P, Zhang C, Zheng S, Epstein PN, Miao LN, Cai L. Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice. Am J Physiol Endocrinol Metab; doi:10.1152/ ajpendo.00430.2012.
8. Cvek B. Proteasome inhibitors. Prog Mol Biol Transl Sci 109: 161-226, 2012.
9. Dreger H, Westphal K, Weller A, Baumann G, Stangl V, Meiners S, Stangl K. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res 83: 354-361, 2009.
10. He X, Kan H, Cai L, Ma Q. Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol 46: 47-58, 2009.
11. Hu J, Klein JD, Du J, Wang XH. Cardiac muscle protein catabolism in diabetes mellitus: activation of the ubiquitin-proteasome system by insulin deficiency. Endocrinology 149: 5384-5390, 2008.
12. Khullar M, Al-Shudiefat AA, Ludke A, Binepal G, Singal PK. Oxidative stress: a key contributor to diabetic cardiomyopathy. Can J Physiol Pharmacol 88: 233-240, 2010.
13. Kis A, Yellon DM, Baxter GF. Role of nuclear factor-κB activation in acute ischaemia-reperfusion injury in myocardium. Br J Pharmacol 138: 894-900, 2003.
14. Lee JM, Johnson JA. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 37: 139-143, 2004.
15. Li B, Liu S, Miao L, Cai L. Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy. Exp Diabetes Res 2012: 216512, 2012.
16. Liu H, Yu S, Xu W, Xu J. Enhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes mellitus. Arterioscler Thromb Vasc Biol 32: 2131-2140, 2012.
17. Luo H, Wu Y, Qi S, Wan X, Chen H, Wu J. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 72: 196-202, 2001.
18. Luo ZF, Qi W, Feng B, Mu J, Zeng W, Guo YH, Pang Q, Ye ZL, Liu L, Yuan FH. Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome. Life Sci 88: 512-520, 2011.
19. Ma Y, Chen B, Liu D, Yang Y, Xiong Z, Zeng J, Dong Y. MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-κB/TGFβ1 pathway. Biochem Pharmacol 81: 1228-1236, 2011.
20. Maier HJ, Schips TG, Wietelmann A, Kruger M, Brunner C, Sauter M, Klingel K, Bottger T, Braun T, Wirth T. Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci USA 109: 11794-11799, 2012.
21. Marcos NT, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin-Lepers A, Almeida R, Silva F, Morais V, Costa J, Kihlberg J, Clausen H, Reis CA. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res 64: 7050-7057, 2004.
22. Marfella R, Di Filippo C, Portoghese M, Siniscalchi M, Martis S, Ferraraccio F, Guastafierro S, Nicoletti G, Barbieri M, Coppola A, Rossi F, Paolisso G, D'Amico M. The ubiquitin-proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: the role of glycemic control. Cardiovasc Pathol 18: 332-345, 2009.
23. Matsuo Y, Sawai H, Ochi N, Yasuda A, Sakamoto M, Takahashi H, Funahashi H, Takeyama H, Guha S. Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-κB activity. Dig Dis Sci 55: 1167-1176, 2010.
24. Meiners S, Ludwig A, Lorenz M, Dreger H, Baumann G, Stangl V, Stangl K. Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med 40: 2232-2241, 2006.
25. Moss NC, Tang RH, Willis M, Stansfield WE, Baldwin AS, Selzman CH. Inhibitory κB kinase-β is a target for specific nuclear factor κBmediated delayed cardioprotection. J Thorac Cardiovasc Surg 136: 1274-1279, 2008.
26. Powell SR, Herrmann J, Lerman A, Patterson C, Wang X. The ubiquitin-proteasome system and cardiovascular disease. Prog Mol Biol Transl Sci 109: 295-346, 2012.
27. Rajesh M, Batkai S, Kechrid M, Mukhopadhyay P, Lee WS, Horvath B, Holovac E, Cinar R, Liaudet L, Mackie K, Hasko G, Pacher P. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 61: 716-727, 2012.
28. Sahni SK, Rydkina E, Sahni A. The proteasome inhibitor MG132 induces nuclear translocation of erythroid transcription factor Nrf2 and cyclooxygenase-2 expression in human vascular endothelial cells. Thromb Res 122: 820-825, 2008.
29. Tan Y, Li X, Prabhu SD, Brittian KR, Chen Q, Yin X, McClain CJ, Zhou Z, Cai L. Angiotensin II plays a critical role in alcohol-induced cardiac nitrative damage, cell death, remodeling, and cardiomyopathy in a protein kinase C/nicotinamide adenine dinucleotide phosphate oxidasedependent manner. J Am Coll Cardiol 59: 1477-1486, 2012.
30. Tkachev VO, Menshchikova EB, Zenkov NK. Mechanism of the Nrf2/ Keap1/ARE signaling system. Biochemistry (Mosc) 76: 407-422, 2011.
31. Wang HQ, Liu BQ, Gao YY, Meng X, Guan Y, Zhang HY, Du ZX. Inhibition of the JNK signalling pathway enhances proteasome inhibitorinduced apoptosis of kidney cancer cells by suppression of BAG3 expression. Br J Pharmacol 158: 1405-1412, 2009.
32. +2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res 106: 1117-1128, 2010.
33. Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 147: 4160-4168, 2006.
34. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56: 641-646, 2007.
35. Xu J, Wu Y, Song P, Zhang M, Wang S, Zou MH. Proteasomedependent degradation of guanosine 5=-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation 116: 944-953, 2007.
36. Yu X, Kem DC. Proteasome inhibition during myocardial infarction. Cardiovasc Res 85: 312-320, 2010.
37. Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D, Zhang DD. Therapeutic potential of Nrf2 activators in streptozotocininduced diabetic nephropathy. Diabetes 60: 3055-3066, 2011.
38. Zheng S, Noonan WT, Metreveli NS, Coventry S, Kralik PM, Carlson EC, Epstein PN. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 53: 3248-3257, 2004.
39. Zhou G, Li X, Hein DW, Xiang X, Marshall JP, Prabhu SD, Cai L. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol 52: 655-666, 2008.